PIK3CA and cancer: Having said that dual PI3K-mTOR inhibitors have less toxicity and common symptoms of side effects like nausea, fatigue, vomiting etc., there are very limited dual PI3K/mTOR inhibitors that have advanced the clinical trials for cancer.